Ernest Pharmaceuticals develops programmable bacterial vectors that selectively colonize solid tumors and release therapeutic payloads—including proteins, oncolytic viruses, and tumor antigens—directly within the tumor microenvironment. Their BacID synthetic‑biology platform provides rapid re‑programming, GMP‑compatible manufacturing, and built‑in safety controls for oncology partners seeking targeted delivery solutions.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with advanced solid tumors often have few effective treatment options, and existing systemic therapies can be limited by off‑target toxicity and insufficient tumor penetration.
Solution
Ernest Pharmaceuticals engineers programmable bacteria that selectively home to solid tumors and release therapeutic payloads directly within the tumor microenvironment. The platform uses synthetic‑biology techniques to equip bacterial strains with tumor‑targeting motifs and autonomous lysis circuits, enabling intracellular delivery of protein drugs, oncolytic viruses, or immunogenic antigens. Pre‑clinical studies demonstrate significant reductions in tumor growth and metastasis across multiple cancer models, including pancreatic cancer. The modular BacID system allows rapid re‑programming of bacterial vectors for different therapeutic cargos, facilitating fast iteration of candidate treatments. Production processes are designed for GMP‑compatible scale‑up and include safety safeguards such as auxotrophic dependencies and kill‑switch mechanisms. Data generated from the platform can be integrated into existing pharmaceutical development pipelines to complement chemotherapy, immunotherapy, or radiotherapy regimens.
Target Audience
The primary customers are pharmaceutical and biotechnology companies developing oncology therapeutics, as well as academic research groups conducting pre‑clinical cancer studies that require targeted delivery vectors.
Features
- Engineered Salmonella strains expressing tumor‑homing surface proteins for selective colonization of solid tumor tissue.
- Autonomous lysis circuit that triggers controlled intracellular release of therapeutic payloads upon sensing the tumor microenvironment.
- Modular genetic payload architecture supporting delivery of therapeutic proteins, oncolytic viruses, or tumor‑specific antigens.
- Synthetic‑biology‑based BacID platform enabling rapid re‑programming of bacterial strains for new indications.
- Pre‑clinical validation in murine models showing decreased tumor burden, reduced metastasis, and activation of anti‑tumor immunity.
- Scalable GMP‑compatible bacterial manufacturing process with defined cryopreservation formulation.
- Integrated safety controls, including auxotrophic safeguards and antibiotic‑sensitivity kill‑switches, to limit off‑target persistence.